OBJECTIVES:~Determine the long-term safety and tolerability of VEGF Trap in patients with incurable relapsed or refractory solid tumors or non-Hodgkin's lymphoma with stable or responding disease after receiving treatment on protocol MSKCC-01131.~Determine the biological effect of this therapy on suppressing tumor growth or progression in these patients.~Determine the steady state concentration of VEGF Trap over time in these patients.~Determine whether patients develop antibodies to this therapy during extended exposure.~OUTLINE: This is an extension study for patients who showed evidence of stable disease or complete or partial remission after completing treatment on protocol MSKCC-01131.~Patients continue to receive VEGF Trap subcutaneously once weekly for up to an additional 6 months in the absence of unacceptable toxicity. Patients receive treatment at the same dose level as on protocol MSKCC-01131.~Patients are followed at approximately 30 days.~PROJECTED ACCRUAL: A maximum of 30 patients will be accrued for this study.
RATIONALE: VEGF Trap may stop the growth of solid tumors or non-Hodgkin's lymphoma by stopping blood flow to the cancer.~PURPOSE: Phase I trial to study the effectiveness of VEGF Trap in treating patients who have relapsed or refractory solid tumors or non-Hodgkin's lymphoma.